Key Highlights
•
A new Alzheimer’s drug, lecanemab, has been approved in the UK, but its rollout faces significant practical and funding challenges. This highlights the gap between scientific breakthroughs and making new treatments accessible and affordable for patients in real-world healthcare systems.
Source →
•
Researchers have identified a specific brain receptor, the α1-adrenergic receptor, as playing a key role in how rats perceive the effects of caffeine. This finding helps explain how caffeine works in the brain and could lead to a better understanding of its stimulant and potentially addictive properties.
Source →
•
Scientists are exploring a protein called FABP5 as a promising new target for non-opioid pain relief, effective in animal models for various pain types. This research offers hope for future pain medications that avoid the addiction risks and side effects of current drugs like opioids and steroids.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
